Ovarian Cancer Immunotherapy and Personalized Medicine
| Autor: | Hannah Staats, John Nemunaitis, Susan Morand, Laura Stanbery, Monika Devanaboyina |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2021 |
| Předmět: |
Oncology
medicine.medical_specialty QH301-705.5 medicine.medical_treatment Review Catalysis Inorganic Chemistry Tumor Biomarkers Antigens Neoplasm Internal medicine Biomarkers Tumor Humans Medicine Molecular Targeted Therapy Precision Medicine Physical and Theoretical Chemistry Biology (General) Molecular Biology QD1-999 Spectroscopy Ovarian Neoplasms Clinical Trials as Topic business.industry Clinical study design Organic Chemistry Disease Management General Medicine Immunotherapy medicine.disease Computer Science Applications Chemistry Treatment Outcome ovarian cancer Biomarker (medicine) biomarker Female Disease Susceptibility Personalized medicine immunotherapy business Ovarian cancer Homologous Recombination Deficiency |
| Zdroj: | International Journal of Molecular Sciences, Vol 22, Iss 6532, p 6532 (2021) International Journal of Molecular Sciences |
| ISSN: | 1661-6596 1422-0067 |
| Popis: | Ovarian cancer response to immunotherapy is limited; however, the evaluation of sensitive/resistant target treatment subpopulations based on stratification by tumor biomarkers may improve the predictiveness of response to immunotherapy. These markers include tumor mutation burden, PD-L1, tumor-infiltrating lymphocytes, homologous recombination deficiency, and neoantigen intratumoral heterogeneity. Future directions in the treatment of ovarian cancer include the utilization of these biomarkers to select ideal candidates. This paper reviews the role of immunotherapy in ovarian cancer as well as novel therapeutics and study designs involving tumor biomarkers that increase the likelihood of success with immunotherapy in ovarian cancer. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|